Investigation of the Correlation Between Endocan, Interleukin-10, and Biochemical Parameters in Iraqi Patients with Cardiovascular Diseases

Abstract

The correlation between biomarkers endocan and interleukin-10 (IL-10) in patients with various cardiovascular diseases—angina pectoris, ischemic heart disease, and myocardial infarction—is examined in this work. There were 200 participants overall, 50 in each of the three disease groups and a control group of fifty healthy people. Along with other factors including renal function, glucose metabolism, and lipid profile, the study gauged serum levels of endocan and IL-10. With myocardial infarction patients showing the highest levels, results revealed that all patient groups had notably greater levels of endocan and IL-10 than healthy controls. With greater blood urea and serum creatinine levels than those with ischemic heart disease and angina pectoris, the study revealed that patients with myocardial infarction demonstrated notably impaired renal function. Along with a poorer lipid profile comprising increased total cholesterol, triglycerides, and low-density lipoprotein (LDL) levels, individuals with myocardial infarction also had higher fasting glucose and hemoglobin A1c levels. By comparison, the healthy control group had the lowest levels of these biomarkers and indicators. The results imply that levels of endocan and IL-10 could be markers of the degree and progression of cardiovascular disease. Particularly those with myocardial infarction showed more marked metabolic and renal abnormalities than those with ischemic heart disease or angina pectoris, so highlighting the possible use of these biomarkers in tracking disease severity and supporting clinical management of cardiovascular diseases.

Keywords

• Angina pectoris
• ischemic heart disease
• myocardial infarction
• endocan and Interleukin-10

References

1. [1] O’Sullivan, Jack W., et al. "Polygenic risk scores for cardiovascular disease: a scientific statement from the American Heart Association." Circulation 146.8 (2022): e93-e118.
2. [2]Caroli, Anna, Andrea Remuzzi, and Lilach O. Lerman. "Basic principles and new advances in kidney imaging." Kidney international 100.5 (2021): 1001-1011.
3. [3]Abdulrahim, Jawan W., et al. "Identification of undetected monogenic cardiovascular disorders." Journal of the American College of Cardiology 76.7 (2020): 797-808.
4. [4]Edwards, Elizabeth Skidmore, and Sarah Carson Sackett. "Psychosocial variables related to why women are less active than men and related health implications: supplementary issue: health disparities in women." Clinical Medicine Insights: Women's Health 9 (2016): CMWH-S34668.
5. [5]Gaggini, Melania, Francesca Gorini, and Cristina Vassalle. "Lipids in atherosclerosis: pathophysiology and the role of calculated lipid indices in assessing cardiovascular risk in patients with hyperlipidemia." International journal of molecular sciences 24.1 (2022): 75.‏
6. [6]Haase-Fielitz, Anja, Michael Haase, and Prasad Devarajan. "Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury: a critical evaluation of current status." Annals of clinical biochemistry 51.3 (2014): 335-351.‏
7. [7]Iwańczyk, Sylwia, et al. "Endocan expression correlated with total volume of coronary artery dilation in patients with coronary artery ectasia." Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej 16.3 (2020): 294-299.‏
8. [8]Dawson, Luke P., et al. "Care models for acute chest pain that improve outcomes and efficiency: JACC state-of-the-art review." Journal of the American College of Cardiology 79.23 (2022): 2333-2348.‏

9. [9]La Russa, Daniele, et al. "Tumor necrosis factor (TNF)-α-stimulated gene 6 (TSG-6): A promising immunomodulatory target in acute neurodegenerative diseases." International Journal of Molecular Sciences 24.2 (2023): 1162.‏
10. [10]Joseph, Joshua J., et al. "Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association." Circulation 145.9 (2022): e722-e759.
11. [11]Task Force for the management of COVID-19 of the European Society of Cardiology, et al. "European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis." Cardiovascular Research 118.6 (2022): 1385-1412.
12. [12]Vakhitov, Damir. "Factors Affecting the Thrombolytic-Treatment-Related Outcomes in Patients with Acute Lower Limb Ischaemia." (2020).‏
13. [13]Kahn, Mark R., et al. "Management of cardiovascular disease in patients with kidney disease." Nature Reviews Cardiology 10.5 (2013): 261-273.‏
14. [14]Malekmohammad, Khojasteh, Evgeny E. Bezsonov, and Mahmoud Rafieian-Kopaei. "Role of lipid accumulation and inflammation in atherosclerosis: focus on molecular and cellular mechanisms." Frontiers in cardiovascular medicine 8 (2021): 707529.‏
15. [15]Zhang, Jun. "Biomarkers of endothelial activation and dysfunction in cardiovascular diseases." Reviews in cardiovascular medicine 23.2 (2022): 73.‏
16. [16]Wang, Cong, et al. "Risk factors for acute kidney injury in patients with acute myocardial infarction." Chinese medical journal 132.14 (2019): 1660-1665.‏
17. [17] Sabir, Fakhara, et al. "Nanodiagnosis and nanotreatment of cardiovascular diseases: An overview." Chemosensors 9.4 (2021): 67.‏‏‏‏‏‏‏